Lessons from recent antithrombotic studies and trials in atrial fibrillation
|
|
- Jared Marcus Howard
- 5 years ago
- Views:
Transcription
1 Lessons from recent antithrombotic studies and trials in atrial fibrillation Thromboembolism cause of stroke in AF Lars Wallentin Uppsala Clinical Research Centre (UCR) Uppsala
2 Disclosures for Lars Wallentin Bristol-Myers Squibb Boehringer Ingelheim AstraZeneca GlaxoSmithKline Schering-Plough Eli Lilly & Co. Research grant Research grant Research grant Research grant Research grant Research grant Regado Biosciences Athera Biotechnologies Evolva Consultancy Consultancy Consultancy
3 Atrial fibrillation Most common arrhythmia 1.5% of the population Increases with age Stroke risk Five fold increase at AF Risk related to risk factors Congestive heart failure Hypertension Age > 75 Diabetes S 2 troke Reduced with antithrombotics Aspirin ( 19%) Warfarin ( 64%) Thromboembolism cause of stroke in AF
4 Targets for long-term antithrombotic treatment Warfarin* Rivaroxaban Apixaban Edoxaban Betrixaban Fondaparinux Idraparinux LMWH AT AT Dabigatran Tissue factor Plasma clotting cascade * Prothrombin * Factor Xa * Thrombin * Fibrinogen Aspirin Collagen Thrombin Conformational activation of GPIIb/IIIa Platelet aggregation Fibrin Tx A 2 ADP PAR1 PAR1-inhib Clopidogrel Prasugrel Ticagrelor GPIIb/IIIa inhibitors Thrombus
5 Lessions learnt from recent trials of antithrombotic treatment in AF Suitable trial design Overall benefits and risks with new treatments - New platelet inhibitor treatment - New anticoagulant treatment Importance of comparator - No anticoagulant - Anticoagulant naive - INR control Risk stratification
6 Trial design comparing new agents with warfarin in AF Single, large trial ( ) Event driven 450 primary events Randomized vs Warfarin Double blind, double dummy Non-inferiority (& superiority) Warfarin switchers and starters CHADS-score >=1 or >=2 TTR for warfarin arm 2-3 > 65%
7 Trial design comparing new agents with aspirin in AF Single, large trial (6000) Event driven 225 primary events Randomized vs Aspirin Double blind, placebo controlled Superiority CHADS-score >=1 Warfarin unsuitable, intolerant, bleeding
8 Lessions learnt from recent trials of antithrombotic treatment in AF Suitable trial design Overall benefits and risks with new treatments - New platelet inhibitor treatment - New anticoagulant treatment Importance of comparator - No anticoagulant - Anticoagulant naive - INR control Risk stratification
9 Phase III trial evaluating platelet inhibition in AF Versus warfarin - Clopidogrel + Aspirin (Active-W) Versus aspirin - Clopidogrel + Aspirin (Active-A) 2009
10 ACTIVE Program: Three Trials Documented AF + 1 risk factor: Age 75, Hypertension, Prior stroke/tia, LVEF<45, PAD, Age CAD or diabetes Contra-indications to OAC or Unwilling ACTIVE W ACTIVE A 6500 patients 7500 patients Clopidogrel+ASA vs. OAC Clopidogrel+ASA vs. ASA No Exclusion criteria for ACTIVE I ACTIVE I ~9000 patients Irbesartan vs placebo Partial Factorial Design ACTIVE W Results AHA Meeting: November 14, 1350g
11 Cumulative Hazard Rates Stroke, Non-CNS Systemic Embolism, MI & Vascular Death RR = 1.45 P = Clopidogrel+ASA 5.64 %/year 3.93 %/year OAC # at Risk C+A OAC Years ACTIVE W Results AHA Meeting: November 14, 1350g
12 Cumulative Hazard Rates Major Bleeding 2.4 %/year RR = 1.06 P = %/year OAC Clopidogrel+ASA # at Risk C+A OAC Years ACTIVE W Results AHA Meeting: November 14, 1350g
13 Cumulative Hazard Rates ACTIVE Primary Outcome (Stroke, MI, non-cns Systemic Embolism, Vascular Death) HR=0.89 ( ) p=0.014 Placebo+Aspirin Clopidogrel+Aspirin No. at Risk C+A ASA Years
14 Cumulative Hazard Rates ACTIVE Stroke HR=0.72 ( ) p= Placebo+Aspirin Clopidogrel+Aspirin No. at Risk C+A ASA Years
15 ACTIVE A and W: ACTIVE Stroke Rates and Risk Reductions Treatment VKA C+A Aspirin ACTIVE W (Rate per year) ACTIVE A (Rate per year) RRR versus Aspirin -58% -28% -- RRR versus C+A -42% -- --
16 Phase III trials comparing new anticoagulants in AF Versus Warfarin Direct thrombin inhibition - Ximelagatran (Sportif III & V) 2003, Dabigatran (RELY) 2009 Direct factor Xa inhibition - Rivaroxaban (ROCKET) Nov Apixaban (ARISTOTLE) Aug Edoxaban (ENGAGE-AF TIMI48) 2012? - Betrixaban (start phase III 2011?) 2014? Versus Aspirin - Apixaban (AVERROES) Aug 29, 2010
17 Thrombin Factor Xa Dabigatran Apixaban Pinto et.al Amer Chem Soc 2005 Dabigatran Specific selective competitive direct fiia inhibitor Inhibits free and fibrin-bound fiia activity Oral prodrug with poor oral bioavailability 6.5% T ½ : Dabigatran h (80% renal excretion) Twice a day dosing 1-4 h post-dose for max inhibition of Factor IIa No direct effect on platelet aggregation Apixaban & Rivaroxaban Specific selective competitive direct fxa inhibitor Inhibits free and fibrin-bound fxa & prothrombinase Good oral bioavailability T ½ : Apixaban 12 h, Rivaroxaban 6-9 h Once twice a day dosing 1-4 h post-dose for max inhibition of Factor Xa No direct effect on platelet aggregation
18 RE-LY study design Atrial fibrillation with 1 risk factor Absence of contraindications R Warfarin 1 mg, 3 mg, 5 mg (INR ) N=6022 Dabigatran etexilate 110 mg bid N=6015 Dabigatran etexilate 150 mg bid N=6076 Primary objective: To establish the non-inferiority of dabigatran etexilate to warfarin Minimum 1 year follow-up, maximum of 3 years and mean of 2 years of follow-up Ezekowitz MD, et al. Am Heart J 2009;157: Connolly SJ., et al. N Engl J Med 2009; 361: Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
19 Cumulative hazard rates Time to first stroke / SSE Warfarin Dabigatran etexilate 110 mg Dabigatran etexilate 150 mg RR 0.90 (95% CI: ) p<0.001 (NI) p=0.29 (Sup) RRR 35% RR 0.65 (95% CI: ) p<0.001 (NI) p<0.001 (Sup) Years RR, relative risk; CI, confidence interval; NI, non-inferior; Sup, superior Connolly SJ., et al. N Engl J Med 2009; 361: Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
20 % per year Vascular mortality 3.00 RR 0.90 (95% CI: ) p=0.21 (sup) RR 0.85 (95% CI: ) p=0.04 (sup) RRR 15% D110 mg BID D150 mg BID Warfarin 289/ 6,015 Connolly SJ., et al. N Engl J Med 2009; 361: / 6, / 6,022 Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
21 % per year Major bleeding rates RR 0.80 (95% CI: ) 2.87 p=0.003 (sup) RRR 20% RR 0.93 (95% CI: ) p=0.31 (sup) D110 mg BID D150 mg BID Warfarin 342 / 6, / 6, / 6,022 Connolly SJ., et al. N Engl J Med 2009; 361: Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
22 Number of events Hemorrhagic stroke RR 0.31 (95% CI: ) 50 p<0.001 (sup) RR 0.26 (95% CI: ) p<0.001 (sup) 40 RRR 69% RRR 74% % % % 0 D110 mg BID D150 mg BID Warfarin 6,015 6,076 6,022 Connolly SJ., et al. N Engl J Med 2009; 361: Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
23 Lessions learnt from recent trials of antithrombotic treatment in AF Suitable trial design Overall benefits and risks with new treatments - New platelet inhibitor treatment - New anticoagulant treatment Importance of comparator - No anticoagulant - Anticoagulant naive - INR control Risk stratification
24 Control group No anticoagulant AVERROES 36 countries, 522 centres AF and 1 risk factor, and demonstrated or expected unsuitable for VKA Apixaban 5 mg BID 2.5 mg BID in selected patients R 5,600 patients Double-Blind ASA ( mg/d) Primary Outcome: Stroke or Systemic Embolic Event (SEE) June 10, 2010 stopped interim analysis shows clear evidence of a clinically important reduction in stroke and systemic embolism and an acceptable safety profile compared to aspirin.
25 Cumulative Hazard Rates Interaction Entry vs No Entry OAC on Primary Outcome +Major Bleeding Entry OAC Interaction P = 0.17 No Entry OAC RR = 1.51 P < RR = 1.14 P = 0.45 C+A OAC OAC C+A Years ACTIVE W Results AHA Meeting: November 14, 1350g
26 Interaction VKA experienced vs naive on Primary Outcome (stroke or SE) Non-inferiority p-value Superiority p-value Interaction p-value Dabigatran 110 vs. Warfarin VKA Experience < VKA Naive Dabigatran 150 vs. Warfarin <0.001 < VKA Experience VKA Naive Hazard Ratio's (95% CI)
27 Mean TTR by country
28 Cumulative Hazard Rates Interaction Centre INR Control on Primary Outcome +Major Bleeding % INR in Range Interaction P = <65% INR in Range RR = 1.80 P < RR = 1.06 P = 0.66 C+A OAC OAC C+A Years ACTIVE W Results AHA Meeting: November 14, 1350g
29 % per year Stroke / SSE According to center based time in therapeutic range (cttr) Q1: cttr < 57.1% Q2: cttr % Q3: cttr % Q4: cttr > 72.6% 2,4 1,8 * Interaction p-value (D 110mg BID vs W.) = 0.90 Interaction p-value (D 150mg BID vs W.) = 0.20 *Interaction p evaluated by a multivariable approach with center based TTR as a continuous variable. 1,2 0,6 W D* D W D* D W D* D W D* D Wallentin L., et al. Lancet 2010; in press. Q1 Q2 Q3 Q4 Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
30 % per year Intracranial bleeding According to center based time in therapeutic range (cttr) Q1: cttr < 57.1% Q2: cttr % Q3: cttr % Q4: cttr > 72.6% 1 * Interaction p-value (D 110mg BID vs W.) = 0.71 Interaction p-value (D 150mg BID vs W.) = 0.89 *Interaction p evaluated by a multivariable approach with center based TTR as a continuous variable. 0,75 0,5 0,25 0 W D* D Wallentin L., et al. Lancet 2010; in press. W D* D W D* D W D* D Q1 Q2 Q3 Q Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
31 % per year Total death According to center based time in therapeutic range (cttr) Q1: cttr < 57.1% Q2: cttr % Q3: cttr % Q4: cttr > 72.6% * Interaction p-value (D 110mg BID vs W.) = 0.07 Interaction p-value (D 150mg BID vs W.) = *Interaction p evaluated by a multivariable approach with center based TTR as a continuous variable W D* D W D* D W D* D W D* D Wallentin L., et al. Lancet 2010; in press. Q1 Q2 Q3 Q4 Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
32 Lessions learnt from recent trials of antithrombotic treatment in AF Suitable trial design Overall benefits and risks with new treatments - New platelet inhibitor treatment - New anticoagulant treatment Importance of comparator - No anticoagulant - Anticoagulant naive - INR control Risk stratification
33 CHADS 2 score overall event rates %/year Stroke and systemic embolism 1 0 CHADS 2 No of pts Major bleeding CHADS
34 CHADS-VASC score Lip GYH Thrombosis Haemostasis 2010
35 Stroke and systemic embolism (SE) D110 BID vs. warfarin D150 BID vs. warfarin CHADS2 Annual rate, % D110 D150 WARFARIN P = 0.37 P = Dabigatran Warfarin better better Dabigatran better Warfarin better Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
36 Intracranial bleeding D110 BID vs. warfarin D150 BID vs. warfarin CHADS2 Annual rate, % D110 D150 WARFARIN P = 0.7 P = Dabigatran Warfarin better better Dabigatran better Warfarin better Dabigatran etexilate is in clinical development and not licensed for clinical use in stroke prevention for patients with atrial fibrillation
37 Lessions learnt from recent trials of antithrombotic treatment in AF Optimal trial designs well established Overall benefits and risks with new treatments - New plt inhibitors add to ASA, inferior to OAC - New OAC advantages compared to warfarin Importance of comparator - No anticoagulant - high event rates, not to be used - VKA naïve no importance after 3 months - INR control modulates effects on outcomes Risk stratification - Related to event rates even with OAC treatment - Relative benefits of new OAC consistent over risk strata
38 Future trials of antithrombotic treatment in AF Overall benefits and risks with new treatments - Incremental benefit vs New OAC - Specific benefits vs New OAC - Personalization of treatment with New OAC Importance of comparator - New comparator will be New OAC Risk stratification - Based on clinical and biochemical markers - Personalization of treatment - Importance of genetics should be explored
39 Which flower should I choose? Which is the ideal type for this environment and occasion? Thanks for your attention
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy
New Aspects in the Diagnosis and Treatment of Atrial Fibrillation: Antithrombotic Therapy Hans-Christoph Diener Department of Neurology and Stroke Center University Hospital Essen Germany Conflict of Interest
More informationAnti-thromboticthrombotic drugs
Atrial Fibrillation 2011: Anticoagulation strategies and clinical outcomes Panos E. Vardas President Elect of the ESC, Prof. of Cardiology, University Hospital of Crete Clinical outcomes affected by AF
More informationNew options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital
New options in Stroke Prevention in AF Paul Dorian University of Toronto St Michael s Hospital Disclosures: Honoraria, research support, and consulting f Sanofi, Boehringer-Ingleheim, Portola, BMS, Bayer,
More informationPros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES
Pros and Cons of Individual Agents Based on Large Trial Results: RELY, ROCKET, ARISTOTLE, AVERROES Ralph L. Sacco, MS MD FAAN FAHA Olemberg Family Chair in Neurological Disorders Miller Professor of Neurology,
More informationNOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients. Giancarlo Agnelli
NOAs for stroke prevention in Atrial Fibrillation: potential advantages in the elderly patients Giancarlo Agnelli Internal & Cardiovascular Medicine - Stroke Unit University of Perugia, Italy My talk today
More informationOld and New Anticoagulants For Stroke Prevention Benefits and Risks
Old and New Anticoagulants For Stroke Prevention Benefits and Risks September 15, 2014 Jonathan L. Halperin, M.D. The Cardiovascular Institute Mount Sinai Medical Center Disclosure Relationships with Industry
More informationJoshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine
Joshua D. Lenchus, DO, RPh, FACP, SFHM Associate Professor of Medicine and Anesthesiology University of Miami Miller School of Medicine Antithrombotics Antiplatelets Aspirin Ticlopidine Prasugrel Dipyridamole
More informationNUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni. Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna
NUOVI ANTICOAGULANTI NELL ANZIANO: indicazioni e controindicazioni Mario Cavazza Medicina d Urgenza Pronto Soccorso AOU di Bologna Two major concerns Atrial Fibrillation: Epidemiology The No. 1 preventable
More informationNew drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle
New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle CONCLUSIONS 1. Arrival of new anticoagulants is a Good Thing. CONCLUSIONS 1. Arrival of new anticoagulants
More informationFACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS
New Horizons In Atherothrombosis Treatment 2012 순환기춘계학술대회 FACTOR Xa AND PAR-1 BLOCKER : ATLAS-2, APPRAISE-2 & TRACER TRIALS Division of Cardiology, Jeonbuk National University Medical School Jei Keon Chae,
More informationD E A R. W Aspirin. AF New Anticoagulants: Todays Aims
AF New Anticoagulants: Todays Aims 1. Characterize the new AC 2. Know critical differences 3. Know the latest study findings in AF 4. Ask critical questions on TTR, OAC naive pts Compliance and dosing
More informationEvents after discontinuation of randomized treatment at the end of the ARISTOTLE trial
Events after discontinuation of randomized treatment at the end of the ARISTOTLE trial Christopher Granger, John Alexander, Michael Hanna, Jerry Wang, Puneet Mohan, Jack Lawrence, Elaine Hylek, Jack Ansell,
More informationWhen and how to combine antiplatelet agents and anticoagulant?
When and how to combine antiplatelet agents and anticoagulant? Christophe Beauloye, MD, PhD Head, Division of Cardiology Cliniques Universitaires Saint-Luc Brussels, Belgium Introduction Anticoagulation
More informationStepheny Sumrall, FNP, AGACNP Cardiovascular Clinic of Hattiesburg
Novel Oral Anticoagulants Analyzing Clinical Trial Findings of the Efficacy and Safety Profiles of Novel Anticoagulants for the Treatment of Atrial Fibrillation and Prevention of Stroke Stepheny Sumrall,
More informationIndications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute
Indications of Anticoagulants; Which Agent to Use for Your Patient? Marc Carrier MD MSc FRCPC Thrombosis Program Ottawa Hospital Research Institute Disclosures Research Support/P.I. Employee Leo Pharma
More informationIndividual Therapeutic Selection Of Anti-coagulants And Periprocedural. Miguel Valderrábano, MD
Individual Therapeutic Selection Of Anti-coagulants And Periprocedural Management Miguel Valderrábano, MD Outline Does the patient need anticoagulation? Review of clinical evidence for each anticoagulant
More informationDebate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF
Debate: New Generation Anti-Coagulation Agents are a Better Choice than Warfarin in the Management of AF Bradley P. Knight, MD Director of Cardiac Electrophysiology Bluhm Cardiovascular Institute Northwestern
More informationWarfarin Therapy in AF INR Control vs Outcome. Assist. Prof. Surakit Nathisuwan
10 th ACCP, Singapore: 11 July 2010 The Great Debate: Is Obsolete? Supporter s View Assist. Prof. Surakit Nathisuwan Clinical Pharmacy Division Department of Pharmacy Faculty of Pharmacy, Mahidol University
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationIs There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger
Is There a Role For Pharmacokinetic/ Pharmacodynamics Guided Dosing For Novel Anticoagulants? Christopher Granger 1 Disclosures Research contracts: Armetheon, AstraZeneca, Bayer, Boehringer Ingelheim,
More informationAtrial Fibrillation in the Emergency Department
Atrial Fibrillation in the Emergency Department Disclosures Edward Jauch, MD MS Research support National Institutes of Health funding (multiple trials) Novo Nordisk (drug in kind) STOP-IT Study Genentech
More informationClinical issues which drug for which patient
Anticoagulants - a matter of heart! Towards a bright future? Clinical issues which drug for which patient Sabine Eichinger Dept. of Medicine I Medical University of Vienna/Austria Conflicts of interest
More informationADVANCES IN ANTICOAGULATION
ADVANCES IN ANTICOAGULATION The Clinicians Perspective Claudine M. Lewis Cardiologist OUTLINE Indications for anticoagulants Review - Physiology of Hemostasis Types of anticoagulants New anticoagulants
More informationAtrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015
Atrial Fibrillation: Risk Stratification and Treatment New Cardiovascular Horizons St. Louis September 19, 2015 Christopher E. Bauer, MD, FACC, FHRS SSM Health Heart & Vascular Care Clinical Cardiac Electrophysiology
More informationThrombosis and Thromboembolsim October Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy
Thrombosis and Thromboembolsim October 2012 Stroke Prevention in Atrial Fibrillation Risk Stratification and Choice of Antithrombotic Therapy Christian T. Ruff, MD, MPH TIMI Study Group Brigham and Women
More informationAnticoagulant therapy, coumadines or direct antithrombins
ATRIAL FIBRILLATION (AF) Anticoagulant therapy, coumadines or direct antithrombins Felicita Andreotti, MD PhD Aggregated Professor Dept of Cardiovascular Sciences, Catholic University, Rome, IT Consultant
More informationNew oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials
New oral factor Xa inhibitors. Lessons from AVERROES and ARISTOTLE trials Dimitri Richter, MD, FESC, FAHA Head of Cardiac Dept., Athens Euroclinic General Secretary of Hellenic Lipidology Society Member
More informationWhich drug do you prefer for stable CAD? - P2Y12 inhibitor
Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,
More informationAntithrombotic therapy in the ACS patient with atrial fibrillation
Antithrombotic therapy in the ACS patient with atrial fibrillation Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Emergency Medicine Wilhelminenhospital Vienna, Austria Great Minds,
More informationDavid Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy
David Stewart, PharmD, BCPS Assistant Professor of Pharmacy Practice East Tennessee State University Bill Gatton College of Pharmacy stewardw@etsu.edu At the conclusion of this program, the audience should
More informationAnticoagulation: Novel Agents
Anticoagulation: Novel Agents Scott C. Woller, MD Medical Director, Anticoagulation Management, Intermountain Healthcare Central Region, co-director Venous Thromboembolism Program, Intermountain Medical
More informationAnticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging
Anticoagulation with Direct oral anticoagulants (DOACs) and advances in peri-procedural interruption of anticoagulation-- Bridging Scott C. Woller, MD Co-Director, Thrombosis Program Intermountain Medical
More informationNeuroPI Case Study: Anticoagulant Therapy
Case: An 82-year-old man presents to the hospital following a transient episode of left visual field changes. His symptoms lasted 20 minutes and resolved spontaneously. He has a normal neurological examination
More informationA Clinical Context Report
Stroke Prevention in Atrial Fibrillation An Expert Commentary With Kenneth W. Mahaffey, MD A Clinical Context Report Stroke Prevention in Atrial Fibrillation Expert Commentary Jointly Sponsored by: and
More informationDisclosure. Objectives. New Anticoagulants 6/5/2014 GHASSAN HADDAD M.D FHM. South Miami hospital Director of the Anticoagulation clinic.
/5/1 New Anticoagulants: Opportunities, Challenges and Practical Considerations GHASSAN HADDAD M.D FHM. Chief of Hospital Medicine i South Miami hospital Director of the Anticoagulation clinic. Financial
More informationESC Congress 2012, Munich
ESC Congress 2012, Munich Anticoagulation in Atrial Fibrillation 2012: Which Anticoagulant for Which Patient? Stefan H. Hohnloser J.W. Goethe University Frankfurt am Main S.H.H. has served as a consultant,
More informationTroponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy. Ziad Hijazi, MD
Troponin I elevation increases the risk of death and stroke in patients with atrial fibrillation a RE-LY substudy Ziad Hijazi, MD Uppsala Clinical Research Center (UCR) Uppsala University, Sweden Co-authors:
More informationACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium
ACS: What happens after the acute phase? Frans Van de Werf, MD, PhD Leuven, Belgium 4/14/2011 Cumulative death rates in 3721 ACS patients from UK and Belgium at ± 5 year (GRACE) 25 20 15 19% TOTAL 14%
More informationA Patient Unsuitable for VKA Treatment
Will Apixaban change practice in atrial fibrillation? A Patient Unsuitable for VKA Treatment Professor Yoseph Rozenman The E. Wolfson Medical Center Jerusalem June 2013 Disclosures I have the following
More informationNOAC trials for AF: A review
NOAC trials for AF: A review Chern-En Chiang, MD, PhD, FACC, FESC General Clinical Research Center Division of Cardiology Taipei Veterans General Hospital National Yang-Ming University Taipei, Taiwan Presenter
More informationINR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA
INR as a Biomarker: Anticoagulation in Atrial Fib, Heart Failure, and Cardiovascular Disease Daniel Blanchard, MD, FACC, FAHA Professor of Medicine Director, Cardiology Fellowship Program Sulpizio Cardiovascular
More informationAnticoagulation: A Changing Landscape. Kelly Matsuda Pharm.D. July 16, Kelly Matsuda Pharm.D. July 16, 2011
Anticoagulation: A Changing Landscape Kelly Matsuda Pharm.D. July 16, 2011 Kelly Matsuda Pharm.D. July 16, 2011 Objectives Review epidemiology of stroke/tia and atrial fibrillation. Review of warfarin
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationNew Antithrombotic Agents DISCLOSURE
New Antithrombotic Agents DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None Research Alexion (PNH) delought@ohsu.edu Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University What
More informationTHROMBOTIC DISORDERS: The Final Frontier
THROMBOTIC DISORDERS: The Final Frontier Jeffrey I. Weitz, MD, FRCP(C), FACP Professor of Medicine and Biochemistry McMaster University Canada Research Chair in Thrombosis Heart & Stroke Foundation/ J.F.
More informationTRIPLE THERAPY, NOACs with concurrent indication for DAPT. Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust
TRIPLE THERAPY, NOACs with concurrent indication for DAPT Paul Wright Lead Cardiac Pharmacist The Heart, UCLH NHS Foundation Trust Content Why consider triple therapy What we know of triple therapy Current
More informationADC Slides for Presentation 02/10/2017
ADC 2017 Slides for Presentation ANTI THROMBOTIC THERAPY FOR NON VALVULAR ATRIAL FIBRILLATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: CURRENT VIEWS Martin A. Alpert, MD Brent M. Parker Professor of Medicine
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More informationDIRECT ORAL ANTICOAGULANTS
2017 Cardiovascular Symposium DIRECT ORAL ANTICOAGULANTS ERNESTO UMAÑA, MD, FACC ORAL ANTICOAGULANTS Vitamin K Antagonists (VKAs): Warfarin Non Vitamin K Antagonists Direct oral anticoagulants Novel Oral
More informationESC Heart & Brain Workshop
Supported by Bayer, Bristol-Myers Squibb and Pfizer Alliance, Boehringer Ingelheim, Daiichi Sankyo Europe GmbH and Medtronic in the form of educational grants. The scientific programme has not been influenced
More informationMODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC
MODULE 1: Stroke Prevention in Atrial Fibrillation Benjamin Bell, MD, FRCPC Specialty: General Internal Medicine Lecturer, Department of Medicine University of Toronto Staff Physician, General Internal
More informationUtilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention
Utilizing Anticoagulants for Atrial Fibrillation Related Stroke Prevention Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania
More informationDirect Oral Anticoagulants An Update
Oct. 26, 2017 Direct Oral Anticoagulants An Update Kathleen Heintz, DO, FACC Assistant Professor of Medicine Cooper Heart Institute Direct Oral Anticoagulants: DISCLAIMERS No Conflicts of Interest So what
More informationScoring Systems in AF 8/10/2016. Strategies in the Prevention of Atrial Fibrillation-Related Strokes. Overview
Strategies in the Prevention of Atrial Fibrillation-Related Strokes Rajat Deo, MD, MTR Assistant Professor of Medicine Division of Cardiology, Electrophysiology Section University of Pennsylvania September
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationNew Strategies in the World of Anticoagulant Therapy. October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center
New Strategies in the World of Anticoagulant Therapy October 13, 2012 Elaine M. Hylek, MD, MPH Boston University Medical Center Presenter Disclosure Information Elaine M. Hylek, MD, MPH Research: NIH/NINDS,
More informationRole of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion
Role of NOACs in AF Management. From Evidence to Real World Data Focus on Cardioversion John Rickard MD, MPH Staff Electrophysiologist Cleveland Clinic Agenda NOACs: Update on Real World Data NOAC reversal:
More informationChapter 1 Introduction
Chapter 1 Introduction There are several disorders which carry an increased risk of thrombosis, clots that interfere with normal circulation, including: venous thromboembolism (VTE), comprising both deep
More informationEngage AF-TIMI 48. Edoxaban in AF: What can we expect? Cardiology Update John Camm. St. George s University of London United Kingdom
Cardiology Update 2013 N S N O N H O H N S1 pocket Aryl binding N site O O N H N Cl Engage AF-TIMI 48 Edoxaban in AF: What can we expect? John Camm St. George s University of London United Kingdom Advisor
More informationPCI in Patients with AF Optimizing Oral Anticoagulation Regimen
PCI in Patients with AF Optimizing Oral Anticoagulation Regimen Walid I. Saliba, MD Director, Atrial Fibrillation Center Heart and Vascular Institute Cleveland Clinic 1 Epidemiology and AF and PCI AF and
More informationAims. AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies
Aims AF and Stroke risk Guidance re anticoagulation Novel oral anticoagulants (NOACs) in non-valvular AF (NVAF) Practical Issues Patient Case Studies AF and Stroke AF prevalence approx doubles with each
More informationANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION
ANTI-THROMBOTIC THERAPY in NON-VALVULAR ATRIAL FIBRILLATION Colin Edwards Auckland Heart Group Waitemata Health June 2015 PFIZER Lecture series Disclosures EPIDEMIOLOGY Atrial fibrillation is the most
More informationNew Antithrombotic Agents
New Antithrombotic Agents Tom DeLoughery, MD FACP FAWM Oregon Health and Sciences University DISCLOSURE Relevant Financial Relationship(s) Speaker Bureau None What I am Talking About 1. New Antithrombotic
More informationRobert C. Welsh, MD, FRCPC Professor of Medicine, University of Alberta Zone Clinical Department Head, Cardiac Sciences
Managing Atrial Fibrillation and ACS/PCI Applying New Evidence to Clinical Practice Dual Anti-Thrombotic Therapy in Acute Coronary Syndromes (ACS) and Afib + PCI/ACS Patients Robert C. Welsh, MD, FRCPC
More informationWhat s new with DOACs? Defining place in therapy for edoxaban &
What s new with DOACs? Defining place in therapy for edoxaban & Use of DOACs in cardioversion Caitlin M. Gibson, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy University of North Texas
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST How to manage antiplatelet treatment in patients with diabetes in acute coronary syndrome Lars Wallentin Professor of Cardiology, Chief Researcher Cardiovascular Science
More informationNOAC 2015: What Have We Learned?
NOAC 2015: What Have We Learned? Milan Gupta, MD Canadian Cardiovascular Research Network University of Toronto, McMaster University www.ccrnmd.com Disclosures Honoraria / Research Grants Abbott, Aegerion
More informationIS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS?
IS THERE STILL A PLACE FOR VITAMINE K ANTAGONISTS? J.Y. LE HEUZEY Georges Pompidou Hospital, René Descartes University, Paris H E G P Munich, August 27, 2012 Disclosure Consultant / Conferences / Advisory
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC DEBATE: DOAC vs Good Old Warfarin André Roussin MD, FRCP, CSPQ CHUM and ICM/MHI Associate professor University of Montreal A. Roussin
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition ACOFP - The Heart of the Matter - An Evidence
More informationcontroversies in anticoagulation: optimizing outcome for atrial fibrillation
controversies in anticoagulation: optimizing outcome for atrial fibrillation SUNDAY, NOVEMBER 13, 2016 WESTIN HOTEL NEW ORLEANS CANAL PLACE COLLABORATE INVESTIGATE EDUCATE PROVIDING PERSPECTIVE: CURRENT
More informationSecondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012
Secondary Preven-on of Thromboembolic Stroke: Clinical Data and Recommenda-ons from the ESC Atrial Fibrilla-on Guideline Update 2012 Professor Dan Atar Head, Dept. of Cardiology Councillor of the ESC,
More informationΣεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή
Σεμινάπιο Ομάδων Δπγαζίαρ ΟΜΑΓΑ ΔΡΓΑΣΙΑΣ ΗΛΔΚΤΡΟΦΥΣΙΟΛΟΓΙΑΣ ΚΑΙ ΒΗΜΑΤΟΓΟΤΗΣΗΣ Κολπική μαπμαπςγή Δξελίξειρ ζηην ανηιπηκηική αγωγή ζε αζθενείρ με κολπική μαπμαπςγή Ξςδώναρ Σωηήπιορ Μονάδα Δμθπαγμάηων και
More informationState of the Art in the ACS Atrial Fibrillation Overlap Syndrome
State of the Art in the ACS Atrial Fibrillation Overlap Syndrome C. Michael Gibson, M.S., M.D. Professor of Medicine, Harvard Medical School Chief, Clinical Research, Beth Israel Deaconess CV Division
More informationAtrial Fibrillation. 2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018
2 nd Annual National Hospitalist Conference San Antonio, TX September 7, 2018, MSc, FACP, SFHM Division of Hospital Medicine Henry Ford Hospital Detroit, USA Clinical Associate Professor of Medicine Wayne
More informationAnticoagulation Beyond Coumadin
Anticoagulation Beyond Coumadin Saturday, September 21, 2013 Crystal Mountain Resort and Spa Pratik Bhattacharya MD, MPH Stroke Neurologist, Michigan Stroke Network; Assistant Professor of Neurology; Wayne
More informationFINAL CDEC RECOMMENDATION
FINAL CDEC RECOMMENDATION APIXABAN (Eliquis Bristol-Myers Squibb Canada and Pfizer Canada Inc.) New Indication: Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation Recommendation:
More informationManagement of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many?
Management of Patients with Atrial Fibrillation and Stents: Is Three Drugs Too Many? Neal S. Kleiman, MD Houston Methodist DeBakey Heart and Vascular Center, Houston, TX Some Things Are Really Clear 2013
More informationPharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO
Pharmacologic Agents to Prevent Stroke in Non-Valvular Atrial Fibrillation and PFO Gregg W. Stone, MD Columbia University Medical Center The Cardiovascular Research Foundation Disclosures None Risk of
More informationModeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD
Modeling the Risk of Stroke and Bleeding in Atrial Fibrillation: What Are the Optimal Risk Scores? Roxana Mehran, MD Mount Sinai School of Medicine New York, NY Session II. Weighing the Risks and Benefits
More informationIncreased Levels of D-dimer in Atrial Fibrillation Identify Patients With Higher Risk of Thromboembolic Events and Death
Increased Levels of D-dimer in Atrial Fibrillation Identify Patients With Higher Risk of Thromboembolic Events and Death Christina Christersson, Malin Schollin, John H. Alexander, Bernand J. Gersh, John
More informationNadine Ajzenberg** Marie-Genevieve Huisse** Isabelle Mahé*** Edith Peynaud **** Aurelie Roche* Patricia Esselin* Laurence Auguste-Charlery*
«new oral anticoagulants and brain specificity» Claire Bal dit Sollier * Ariane Davout * Sun-Young Park* Irène Clavijo* Adeline-Zoe Thoux * Ioana Muller* Ludovic Drouet* Nadine Ajzenberg** Marie-Genevieve
More informationA Patient with Chest Pain and Atrial Fibrillation
A Patient with Chest Pain and Atrial Fibrillation Kurt Huber, Vienna, Austria Declaration of Interest Lecturing & Consulting Activities: AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Daiichi
More informationAnticoagulation Therapy in LTC
Anticoagulation Therapy in LTC By: Cynthia Leung, RPh, BScPhm, PharmD. Clinical Consultant Pharmacist MediSystem Pharmacy Jun 11, 2013 Agenda Stroke and Bleeding Risk Assessment Review of Oral Anticoagulation
More informationRelationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial
Relationship between Center Time in Therapeutic Range and Comparative Treatment Effect of Rivaroxaban and Warfarin: Results from the ROCKET AF Trial Jonathan P. Piccini, Frank Harrell, Yulia Lokhnygina,
More informationPRESENTATION TITLE. Case Studies
PRESENTATION TITLE Case Studies 1) SH is a 67 year old male. He has a history of type 2 diabetes, controlled hypertension and peripheral artery disease. He takes naproxen 500mg bd for arthritis and admits
More informationThe Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for
The Treatment of Venous Thromboembolism (VTE): Has Warfarin Met Its Match? Michael P. Gulseth, Pharm. D., BCPS, FASHP Program Director for Anticoagulation Services Sanford USD Medical Center Sioux Falls,
More informationAnticoagulation Update David J. Moliterno, MD
David J., MD Anticoagulant Agents n Cardiovascular Medicine: An Update David J., MD Professor and Chairman Division of Cardiovascular Medicine The University of Kentucky Linda and Jack Gill Heart nstitute
More informationAntithrombotics in Stroke management
Antithrombotics in Stroke management Faculty: Robert Beveridge Relationships with commercial interests: Grants/Research Support: N/A Speakers Bureau/Honoraria: Astra Zeneca, Bayer, Boerhinger Ingelheim,
More informationTherapeutic Advances for the Management of Thrombosis: Navigating the New Paradigm. Formulary and Contract Manager SelectHealth
Therapeutic Advances for the Management of Thrombosis: Navigating the New Paradigm Jeffrey D Dunn PharmD MBA Jeffrey D. Dunn, PharmD, MBA Formulary and Contract Manager SelectHealth Faculty Disclosure
More informationAntithrombotic Efficacy and Safety of Dabigatran Etexilate
130419 Luncheon Symposium_2013 춘계심장학회 Antithrombotic Efficacy and Safety of Dabigatran Etexilate Hui-Nam Pak, MD, PhD. Division of Cardiology Yonsei University Health System Atrial Fibrillation Risk of
More informationNew Oral Anticoagulant Drugs in the Prevention of DVT
New Oral Anticoagulant Drugs in the Prevention of DVT Targets for Anticoagulants ORAL DIRECT VKAs inhibit the hepatic synthesis of several coagulation factors Rivaroxaban Apixaban Edoxaban Betrixaban X
More informationNovel Anticoagulants PHYSICIANS UPDATE 2014
Novel Anticoagulants PHYSICIANS UPDATE 2014 Farouk Mookadam MD FRCPC FACC MSc Professor College of Medicine Mayo Consultant Cardiovascular Diseases Medical Director Anticoagulation Clinic Assoc Programme
More informationThe Role of NOACs in AF: What do We Know 4 Years After the RE-LY Study?
The Role of NOACs in AF: What do We Know 4 Years After the RE-LY Study? Michael Glikson, MD, FACC, FESC Davidai Arrhythmia Center Leviev Heart Center Israel June 2013 Disclosures No relevant Disclosures
More informationOral Anticoagulants Update. Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation
Oral Anticoagulants Update Elizabeth Renner, PharmD, BCPS, BCACP, CACP Outpatient Cardiology and Anticoagulation Objectives List the direct oral anticoagulant (DOAC) drugs currently available Describe
More informationConflict of interest statement
Risk of stroke, systemic embolism or death according to heart failure and left ventricular function status in patients with atrial fibrillation: results of the ARISTOTLE trial J.J.V. McMurray 1, B. Lewis
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationNAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING
NAVIGATING THROMBOSIS AND BLEEDING AT THE INTERSECTION OF ATRIAL FIBRILLATION AND CORONARY STENTING Snehal H. Bhatt, Pharm.D., BCPS-AQ Cardiology, FASHP, AACC Associate Professor of Pharmacy Practice MCPHS
More informationDrug Class Monograph
Drug Class Monograph Class: Oral Anticoagulants Drug: Coumadin (warfarin), Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban), arelto (rivaroxaban) Formulary Medications: Eliquis (apixaban),
More informationOral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death!
Oral anticoagulation/antiplatelet therapy in the secondary prevention of ACS patients the cost of reducing death! Robert C. Welsh, MD, FRCPC Associate Professor of Medicine Director, Adult Cardiac Catheterization
More information